EM-9017

EM-9017
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

EM-9017 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications in the treatment of chronic pain and neuropathic disorders. This article provides a comprehensive overview of EM-9017, including its chemical properties, mechanism of action, clinical trials, and potential side effects.

Chemical Properties

EM-9017 is a synthetic compound with a complex molecular structure. It is classified as a small molecule drug, designed to interact with specific receptors in the central nervous system. The chemical formula of EM-9017 is C₂₀H₂₅N₃O₃, and it has a molecular weight of 355.44 g/mol.

Mechanism of Action

EM-9017 functions primarily as a selective agonist for the GABA_B receptor, a type of G-protein coupled receptor that plays a crucial role in modulating neurotransmission in the brain. By activating these receptors, EM-9017 enhances inhibitory neurotransmission, which can lead to a reduction in neuronal excitability and a decrease in the perception of pain.

Clinical Trials

EM-9017 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with chronic pain conditions, such as fibromyalgia and diabetic neuropathy. Preliminary results have shown promise, with many participants reporting significant pain relief and improved quality of life.

Potential Side Effects

As with any pharmacological agent, EM-9017 may cause side effects. Commonly reported adverse effects include dizziness, fatigue, and nausea. More serious side effects, although rare, may include respiratory depression and hypotension. Ongoing studies aim to further elucidate the safety profile of EM-9017.

Regulatory Status

EM-9017 has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The drug is currently available only for research purposes and is not yet marketed for clinical use.

Also see

• Chronic pain management
• GABA receptor
• Neuropathic pain
• Pharmacology

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology